2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
65
Sarcoma
40
Neoplasm Metastasis
22
Neoplasms
20
Ovarian Neoplasms
17
Breast Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Recurrence
7
Leiomyosarcoma
7
Kidney Neoplasms
7
Melanoma
6
Liposarcoma
6
Hemangiosarcoma
6
Glioblastoma
6
Fallopian Tube Neoplasms
6
Thyroid Neoplasms
5
Prostatic Neoplasms
5
Neurofibrosarcoma
5
Lung Neoplasms
5
Urinary Bladder Neoplasms
4
Solid Tumors
4
Sarcoma, Synovial
4
Pancreatic Neoplasms
4
Osteosarcoma
4
Histiocytoma, Malignant Fibrous
4
Dermatofibrosarcoma
4
Clear-cell metastatic renal cell carcinoma
4
Chondrosarcoma, Extraskeletal Myxoid
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
delta 24-sterol reductase
1
decitabine and cedazuridine drug combination
1
daratumumab
1
apalutamide
1
Validation Studies as Topic
1
Trastuzumab
1
Tape Recording
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Preoperative Exercise
1
Pilot Projects
1
Opdualag
1
Nutritional Support
1
Nivolumab
1
Injections, Subcutaneous
1
Focus Groups
1
Exercise
1
Ethanol
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Adiposity
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Patient Preference
×
pazopanib
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts